Pfizer Creates Separate, Internal, Global Innovative and Established Pharma Businesses Pakistan Part of the Established Pharma Business in Asia Pacific
Pfizer Pakistan – January 1, 2014: In July 2013, Pfizer Inc. globally announced plans to move forward to internally separate its commercial operations into three business segments, two of which include Innovative business lines and a third which includes the Established Products business line. Each of the three segments fully integrates the emerging markets business unit. The changes have been implemented in January 2014 in various countries where Pfizer operates, while some await local consultations with work councils.
Pfizer’s Global Innovative Pharma (GIP) business, led by Geno Germano, includes products across multiple therapeutic areas that are expected to have market exclusivity beyond 2015. The therapeutic areas include Inflammation and Immunology, CV/Metabolic, Neuroscience and Pain, Rare Diseases and Women’s /Men’s Health.
The other Innovative business segment includes Vaccines, Oncology and Consumer Healthcare, and is led by Albert Bourla. Each of these businesses will operate as a separate global business and require distinct specialization in terms of the science, talent, and market approach required to deliver value to consumers and patients.
The Global Established Pharma (GEP) Business segment, led by John Young, includes products that are positioned to provide patients access to effective, lower-cost, high-value treatments. In addition to products that have lost market exclusivity, it includes mature, patent-protected products that are expected to lose exclusivity through 2015 in most major markets, biosimilars and current and future established products collaborations.
Pakistan is now a part of the Global Established Pharma (GEP) Business segment in the Growth Markets sub-region of Asia Pacific. The Pfizer affiliate in Pakistan is led by Dr Farid Khan.